DOI QR코드

DOI QR Code

Identification and Antibiotic Susceptibility of the Bacteria from Non-odontogenic Infectious Lesions

  • Kim, Yong Min (Department of Oral & Maxillofacial Surgery, Dream Dental Clinic) ;
  • Kim, Jae-Jin (Department of Dentistry, College of Medicine, Chungnam National University) ;
  • Kim, Mija (Department of Nursing, Pai Chai University) ;
  • Park, Soon-Nang (Korean Collection for Oral Microbiology, Department of Oral Biochemistry, and Oral Biology Research Institute, School of Dentistry, Chosun University) ;
  • Kim, Hwa-Sook (Department of Dental Hygiene, Chunnam Techno University) ;
  • Kook, Joong-Ki (Korean Collection for Oral Microbiology, Department of Oral Biochemistry, and Oral Biology Research Institute, School of Dentistry, Chosun University) ;
  • Kim, Hak Kyun (Department of Dentistry, College of Medicine, Chungnam National University)
  • 투고 : 2014.03.25
  • 심사 : 2014.06.03
  • 발행 : 2014.06.30

초록

The purpose of this study was to isolate and identify bacteria from the 4 patients with non-odontogenic infectious lesions (mucormycosis, chronic inflammation from wound infection, and two actinomycosis) and determine their antimicrobial susceptibility against eight antibiotics. Bacterial culture was performed under three culture conditions (anaerobic, $CO_2$, and aerobic incubator). The bacterial strains were identified by 16S rRNA gene (16S rDNA) sequence comparison analysis method. For investigating the antimicrobial susceptibility of the bacteria against eight antibiotics, penicillin G, amoxicillin, tetracycline, cefuroxime, erythromycin, clindamycin, vancomycin, and Augmentin$^{(R)}$ (amoxicillin + clavulanic acid), minimum inhibitory concentration (MIC) measurement was performed using broth microdilution assay. Nosocomial pathogens such as Enterococcus faecalis, Klebsiella pneumoniae, Bacillus subtilis, and Neisseria flavescens were isolated from mucormycosis. Veillonella parvula, Enterobacter hormaechei, and Acinetobacter calcoaceticus were isolated from chronic inflammatory lesion. Actinomyces massiliensis was isolated from actinomycosis in parotid gland. Capnocytophaga ochracea was isolated from actinomycosis in buccal region in anaerobic condition. There was no susceptible antibiotic to all bacteria in mucormycosis. Tetracycline was susceptible to all bacteria in chronic inflammation. C. ochracea was resistant to vancomycin and penicillin G; and other antibiotics showed susceptibility to all bacteria in actinomycosis. The results indicated that the combined treatment of two or more antibiotics is better than single antibiotic treatment in mucormycosis, and penicillin is the first recommended antibiotic to treat actinomycosis.

키워드

참고문헌

  1. Paster BJ, Boches SK, Galvin JL, Ericson RE, Lau CN, Levanos VA, Sahasrabudhe A, Dewhirst FE. Bacterial diversity in human subgingival plaque. J Bacteriol. 2001;183:3770-3783. https://doi.org/10.1128/JB.183.12.3770-3783.2001
  2. Sandor GK, Low DE, Judd PL, Davidson RJ. Antimicrobial treatment opition in the management of odontogenic infection. J Can Dent Assoc. 1998; 64:508-514.
  3. Jerry L, Lionel M. Oral and maxillofacial surgery, Vol VII. WB Saunders, Philadelphia, 2000;77-117.
  4. Kim KS, Lee DK. Oral and Maxillofacial Infections. 2nd Ed, Goonja Publishing Co., Seoul, 1992, 131-212.
  5. Baker KA, Fotos PG. The management of odontogenic infection. A rationale for appropriate chemotheraphy. Dent Clin North Am. 1994;38:689-706.
  6. Kuriyama T, Karasawa T, Nakagawa K. Bacteriologic features and antimicrobial susceptibility in isolates from orofacial odontogenic infection. Oral Surg Oral Med Oral Pathol. 2000;90:600-608. https://doi.org/10.1067/moe.2000.109639
  7. Sabiston CB, Grigsby WR, Segerstron N. Bacterial study of pyogenic infections of dental origin. Oral Surg. 1976;41:430-436. https://doi.org/10.1016/0030-4220(76)90269-3
  8. Topazian RG, Goldberg MH. Management of infection of the oral and maxillofacial regions, 2nd Ed, WB Saunders, Philadelphia, 1981, 173-266.
  9. Jones AC, Bentsen TW, Freedman PD. Mucormycosis of the oral cavity. Oral Surg Oral Med Oral Pathol. 1993;75:455-460. https://doi.org/10.1016/0030-4220(93)90170-9
  10. Salisbury PL, Caloss R Jr, Cruz JM, Powell BL, Cole R, Kohut RI. Mucormycosis of the mandible after dental extraction in a patient with acute myelogenous leukemia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;83:340-344. https://doi.org/10.1016/S1079-2104(97)90240-7
  11. Nussbaum ES, Hall WA. Rhinocerebral mucormycosis: Changing patterns of disease. Surg Neurol. 1994;41: 152-156. https://doi.org/10.1016/0090-3019(94)90114-7
  12. Armstrong D. Treatment of opportunistic fungal infections. Clin Infect Dis. 1993;16:1-9. https://doi.org/10.1093/clinids/16.1.1
  13. Adam RD, Hunter G, DiTomasso J, Comerci G. Mucormycosis: emerging prominence of cutaneous infection. Clin Infect Dis. 1994;19:67-76. https://doi.org/10.1093/clinids/19.1.67
  14. Parfrey NA. Improved diagnosis and prognosis of mucormycosis: a clinicopathologic study of 33 cases. Medicine 1986;65:113-123. https://doi.org/10.1097/00005792-198603000-00004
  15. Bennhoff DF. Actinomycosis: Diagnostic and therapeutic consideration and a review of 32 cases. Laryngoscope 1984;94:1198-1217.
  16. Mello KA, Snydman DR, Arora S. Capnocytophaga infection involving a portal-systemic vascular shunt. Dig Dis Sci. 1990;35:909-911. https://doi.org/10.1007/BF01536808
  17. Harrison TR. Principles of internal medicine. 8th Ed, McGraw-hill Kogakusa, Ltd. Tokyo, 1977;938-939.
  18. Brown JR. Human Actinomycosis. A study of 181 subject. Hum. Pathol. 1973;4:319-330. https://doi.org/10.1016/S0046-8177(73)80097-8
  19. Kay EB. Bronchopulmonary Actinomycosis. Ann Int Med. 1947;26:581-593. https://doi.org/10.7326/0003-4819-26-4-581
  20. Davis-Christopher. Textbook of Surgery, 125h 3rd Ed, vol.17 1981:355.
  21. Harvey JC, Caantrell JR, Fisher AM. Actinomycosis: Its recognition and treatment. Ann Intern Med. 1957; 46:868-885. https://doi.org/10.7326/0003-4819-46-5-868
  22. Robbins SL. Pathologic basis of diseases, 2nd Ed, WB Saunders Company, Philadelphia, 1979;455,
  23. Putman HC, Dockery MB, Waugh JW. Abdominal actinomycosis; an analysis of 122 cases. Surgery 1950;28:781-800.
  24. van Winkelhoff AJ, Herrera D, Oteo A, Sanz M. antimicrobial profiles of periodontal pathogens isolated from periodontitis patients in The Netherland and Spain. J Clin Periodontol. 2005;32:893-898. https://doi.org/10.1111/j.1600-051X.2005.00782.x
  25. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual, 2nd ed., Cold Spring Harbor Laboratory Press, New York, 1988.
  26. Jorgensen JH, Turnidge JD, Washington A. Antibacterial susceptibility tests: dilution and disk diffusion methods. In: Murray ER, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, Manual of CLINICAL MICROBIOLOGY, 7th Ed, ASM press, Washington, 1999;1526-1543.
  27. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard-Sixth Edition. CLSI document M7-A6.Wayne Pennsylvania USA. 2005.
  28. Kingdom TT, Tami TA. Actinomycosis of the nasal septum in a patient infected with the human immunodeficiency virus. Otolaryngol Head Neck Surg. 1994;111:130-133. https://doi.org/10.1177/019459989411100123
  29. Brook I. Actinomycosis: diagnosis and management. Med J. 2008;101:1019-1023.
  30. Topazian RG, and Goldberg M. Oral and Maxillofacial infection, 2nd Ed, Philadelohia, PA, Saunders, 1987.
  31. Lerner PI. Susceptibility of pathogenic actinomycetes to antimicrobial compounds. Antimicrob Agents Chemother. 1974;5:302-309. https://doi.org/10.1128/AAC.5.3.302
  32. Pigards N. Precaution against cross-infection during operations for maxillofacial trauma. Br J Oral Maxillofac Surg. 2000;38:110-113. https://doi.org/10.1054/bjom.1999.0145
  33. Bergogne-Berezin E, Towner KJ. Acinectobacter spp. as Nosocomial Pathogens; Microbiological, Clinical, and Epidemiological Features. Clin Microbiol Rev. 1996; 9:148-165.
  34. Arrosagaray PM, Salas C, Morales M, Correas M, Barros JM, Cordon ML. Bilateral abscessed orchiepididymitis associated with sepsis caused by Veillonella parvula and Clostridium perfringens: case report and review of the literature. J Clin Microbiol. 1987;25:1579-1580.
  35. Stock I, Gruger T, Wiedemann B. Natural antibiotics susceptibility of strains of the Enterobacter cloacae complex. Int J Antimicrob Agents 2001;12:537-545.
  36. Kim YG, Kim JD, Ryu DM, Lee BS, Oh JH. Mucormycosis in maxilla: A case report. J Kor Oral Maxillofac Surg. 2004;30:69-73.
  37. Heimdahl A, Nord CE. Treatment of orofacial infections of odontogenic origin. Scand J Infect Dis Suppl. 1985; 46:101-105.
  38. Griffiths GK, VandenBurg MJ, Wight LJ, Gudgeon AC, Kelsey M. Efficacy and tolerability of cefuroxime axetil in patients with upper respiratory tract infections. Curr Med Res Opin. 1987;10:555-561. https://doi.org/10.1185/03007998709108965
  39. Wilson WR. Tetracycline, chloramphenicol, erythromycin, and clindamycin. Mayo Clin Proc. 1977;52:635-640.
  40. Mehrhof AI. Clindamycin an evaluation of its role in dental patients. J Oral Surg. 1976;34:811-817.
  41. Bascones Martinez A, Aguirre Urizar JM, Bermejo Fenoll A, Blanco Carrion A, Gay-Escoda C, Gonzalez-Moles MA, Gutierrez Perez JL, Jimenez Soriano Y, Liebana Urena J, Lopez Marcos JF, Maestre Vera JR, Perea Perez EJ, Prieto Prieto J, de Vicente Rodriguez JC. Consensus statement on antimicrobial treatment of odontogenic bacterial infections. Med Oral Patol Oral Cir Bucal. 2004;9:369-376.